AIM
CRSP icon

ARK Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

ARK Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,300
Closed -$85K – 235
2022
Q3 		$85K Hold
1,300
– – ﹤0.01% 238
2022
Q2 		$75K Hold
1,300
– – ﹤0.01% 339
2022
Q1 		$82K Hold
1,300
– – ﹤0.01% 344
2021
Q4 		$99K Buy
+1,300
New +$114K ﹤0.01% 355

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

ARK Investment Management's CRSP Position: Q1 2026 in Review

ARK Investment Management increased its CRISPR Therapeutics (CRSP) stake by 7.5% in Q1 2026, buying an estimated $41.8M and bringing the position to 11,313,623 shares worth $538M. The position accounts for 4.19% of the portfolio, ranked #3.

ARK Investment Management first reported a position in CRSP in Q2 2017 and has held it in 36 quarters since. The position peaked at $1.59B in Q4 2020. 490 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • ARK Investment Management held 11,313,623 shares of CRISPR Therapeutics worth $538M as of Q1 2026.
  • ARK Investment Management bought 791,566 CRISPR Therapeutics shares in Q1 2026, an estimated $41.8M.
  • CRISPR Therapeutics made up 4.19% of ARK Investment Management's portfolio in Q1 2026, its #3 holding.
  • ARK Investment Management first reported a position in CRISPR Therapeutics in Q2 2017 and has held it in 36 quarters since.
  • ARK Investment Management's CRISPR Therapeutics position peaked at $1.59B in Q4 2020.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on ARK Investment Management's 13F filing for Q1 2026, filed 12 May 2026.